Posts

STAT+: Judge skeptical of arguments against Medicare dr...

STAT's John Wilkerson was in the room as a judge questioned AstraZeneca lawyers ...

Congressmen: This Covid hearing ‘could have been an email’

A Wednesday hearing on Covid origins “could have been an email,” two congressmen...

STAT+: WTO appears close to rejecting a proposed waiver...

The WTO appears close to rejecting a waiver on intellectual property protection ...

Some dementia patients might have reversible symptoms c...

Liver disease can cause symptoms that look like dementia. A new analysis suggest...

We’re naming cancers all wrong, oncology leader says

When cancer treatments are based on genetics rather than the organ tumors are in...

Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an...

This week on "The Readout LOUD" podcast: What makes a blockbuster? Can biotech l...

Updated Covid vaccine has 54% effectiveness, new data s...

New data released Thursday by the CDC suggest that the most recent Covid-19 boos...

Medicare drug price negotiation’s day in court

Today's D.C. Diagnosis newsletter has updates on Medicare's new power to negotia...

Clues from mice could help explain why women face a hig...

A new study highlights the possible role of an RNA molecule in explaining why wo...

STAT+: Raleigh-Durham challenges Boston as biomanufactu...

Like Boston, Raleigh-Durham has elite universities and a talented workforce — pl...

Methadone treatment gets first major update in over 20 ...

To better stave off opioid withdrawal, methadone clinics will be allowed to pres...

Novavax is on thin ice, and the latest update isn’t exa...

Novavax, the company whose corporate missteps repeatedly sidelined an effective ...

STAT+: Pharmalittle: We’re reading about Medicare price...

The Biden administration is making its opening offers to pharmaceutical companie...

STAT+: Biden administration makes opening offers in Med...

Medicare will negotiate discounts for each drug ranging from 25% off list price ...

Opinion: Where do we go from here on digital therapeutics?

Where do we go from here on digital therapeutics?

STAT+: General Catalyst wants to take over a safety-net...

The venture capital firm’s experiment is facing hurdles even before it has start...